.gif)
BioStem Technologies, Inc.
47
BioStem Technologies reported quarterly losses in Q1 and Q2 2026 but exceeded revenue expectations in both quarters. The company’s latest 10-Q filing provides detailed financial figures for Q2 2026.
- BioStem Technologies, Inc. reported a net loss of $8,971,360 and revenues of $7,899,249 for Q2 2026 [S1].
- The company’s basic and diluted EPS were both -$0.52 for the quarter ended June 30, 2026 [S1].
- As of June 30, 2026, BioStem had cash and cash equivalents of $6,962,492 and current assets of $20,781,054, with current liabilities of $21,202,344, resulting in a current ratio of 0.98 and cash ratio of 0.33 [S1].
- Recent news reports confirm BioStem topped revenue expectations in Q1 and Q2 2026 despite reporting losses [N1][N5].
BioStem Technologies, Inc. is a publicly reporting company with recent quarterly financial disclosures through its 10-Q filing as of August 12, 2026. The company reported revenues and net losses for the quarter ended June 30, 2026. Specific details about its sector, industry, and business operations are not disclosed in the available data. The company’s liquidity position shows current liabilities slightly exceeding current assets as of the latest quarter.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. BioStem Technologies, Inc. reported a net loss of approximately $9 million and revenues near $7.9 million for Q2 2026. The company had a current ratio below 1.0 as of June 30, 2026, indicating current liabilities slightly exceeded current assets. Recent news coverage highlights quarterly losses alongside revenue performance surpassing expectations in early 2026 [S1][N1][N5].
The company has demonstrated the ability to generate revenues in the millions and has attracted coverage for its quarterly earnings and insider trading activity, indicating some market interest and operational activity.
BioStem Technologies reported net losses in recent quarters and has a current ratio below 1.0, indicating potential liquidity constraints. Lack of disclosed sector and industry information limits clarity on its business model and competitive positioning.
Information on BioStem Technologies’ competitive advantages or market positioning is not disclosed in the available data, limiting assessment of its moat.
• Liquidity Risk: The current ratio of 0.98 and cash ratio of 0.33 as of June 30, 2026, suggest that current liabilities slightly exceed current assets, which may pose liquidity challenges.
• Profitability Risk: The company reported a net loss of approximately $9 million for Q2 2026, indicating ongoing unprofitability.
• Information Transparency Risk: Limited disclosure of sector, industry, and detailed business operations reduces visibility into the company’s strategic positioning and risks.
Business trends: The company has reported consecutive quarterly losses while generating revenues that surpassed expectations in early 2026.
Execution milestones: Recent SEC filings provide detailed financial disclosures; ongoing quarterly earnings reports maintain transparency.
Key risks: Liquidity pressures due to current liabilities exceeding current assets, sustained unprofitability, and limited public disclosure of business model details.
Moderate visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- BioStem Technologies, Inc. reported a net loss of $8,971,360 for the quarter ended June 30, 2026, according to its 10-Q filing dated August 12, 2026 [S1].
- The company generated revenues of $7,899,249 for the same quarter [S1].
- Basic and diluted earnings per share were both -$0.52 for Q2 2026 [S1].
- As of June 30, 2026, BioStem had cash and cash equivalents of $6,962,492 and current assets totaling $20,781,054 [S1].
- Current liabilities as of June 30, 2026, were $21,202,344, resulting in a current ratio of 0.98 and a cash ratio of 0.33 [S1].
- Recent news reports indicate BioStem Technologies reported losses in Q1 and Q2 2026 but topped revenue expectations in both quarters [N1][N5].
- The company has publicly reported quarterly earnings results and insider trading and hedge fund activity coverage in 2025 and 2026 [N7][N8].
Generated 2026-08-13
- S1 | 2026-08-12 | 10-Q
- N1 | 2026-08-12 | www.nasdaq.com | BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/biostem-technologies-inc-bsem-reports-q2-loss-beats-revenue-estimates
- N2 | 2026-08-11 | www.nasdaq.com | Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/codexis-cdxs-reports-q2-loss-tops-revenue-estimates
- N3 | 2026-08-06 | www.nasdaq.com | Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/novavax-nvax-reports-q2-loss-tops-revenue-estimates
- N4 | 2026-08-05 | www.nasdaq.com | Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/cytek-biosciences-inc-ctkb-reports-q2-loss-tops-revenue-estimates
- N5 | 2026-05-14 | www.nasdaq.com | BioStem Technologies, Inc. (BSEM) Reports Q1 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/biostem-technologies-inc-bsem-reports-q1-loss-tops-revenue-estimates
- N6 | 2026-05-13 | www.nasdaq.com | Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/precigen-inc-pgen-reports-q1-loss-tops-revenue-estimates
- N7 | 2025-05-12 | www.nasdaq.com | $BSEM Earnings Results: $BSEM Reports Quarterly Earnings | https://www.nasdaq.com/articles/bsem-earnings-results-bsem-reports-quarterly-earnings
- N8 | 2025-04-05 | www.nasdaq.com | $BSEM Earnings Preview: Recent $BSEM Insider Trading, Hedge Fund Activity, and More | https://www.nasdaq.com/articles/bsem-earnings-preview-recent-bsem-insider-trading-hedge-fund-activity-and-more
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.
Generated by Valye SEC Pipeline Engine